Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
No waiting
Patient-specific factors that influence choice include: Concurrent diabetes : Patients with type 2 diabetes may have broader access through NHS prescribing pathways BMI and weight loss goals : Higher BMI patients may benefit from agents with greater weight loss efficacy Tolerability : Previous experience with gastrointestinal side effects may guide selection Injection preference : Some patients strongly prefer weekly over daily injections, or oral over injectable formulations Cardiovascular disease : Certain GLP-1 agonists have proven cardiovascular benefits, which may be relevant for high-risk patients Ultimately, the choice should be individualised through shared decision-making between patient and clinician, considering the available evidence, licensed indications, local prescribing policies, and patient preferences
You can learn more about our GLP-1 Weight Loss Plan Online and Meet Your Provider pages to see how our clinician supervises care
The proposed mechanism involves MMP-1, a specific matrix metalloproteinase
The link between GLP-1 agonists and easing symptoms of IBD isnt fully understood yet, but medications like Ozempic and Mounjaro are considered safe for those with Crohns or UC
US$ 24.48
US$ 23.49
US$ 20.72
US$ 20.50
US$ 23.90
